After Hemophilia Deal, UniQure Sees Zolgensma As Model For Huntington’s Gene Therapy
Focused On Long-Term Gene Therapy Leadership
While M&A-hungry investors were disappointed in no sale, uniQure now aims to pivot toward Huntington’s – and sees Zolgensma as an example to follow.
